Previous 10 | Next 10 |
BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis - Annualized Bleeding Rate (ABR) Reduced by 85...
BioMarin to Participate in Two Virtual Investor Conferences in January - Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference: A View from the Top on Thursday, January 6 at 11:00am ET - 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10 at 1:30pm ...
Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...
BioMarin Pharmaceutical (NASDAQ:BMRN) and Skyline Therapeutics will collaborate on developing adeno-associated virus ("AAV") gene therapies for genetic cardiovascular diseases. The collaboration includes discovery and research through to an IND application. Skyline has a AAV gene therapy plat...
BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases PR Newswire SAN RAFAEL, Calif. and SHANGHAI , Dec. 16, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Skyline ...
BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors PR Newswire SAN RAFAEL, Calif. , Dec. 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases...
The following slide deck was published by BioMarin Pharmaceutical Inc. in conjunction with this event. For further details see: BioMarin Pharmaceutical (BMRN) R&D Day 2021 Presentation
Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In BioMarin To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - December 5, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm,...
BioMarin to Hold Virtual R&D Day at 11:00am ET Today BioMarin to Hold Virtual R&D Day at 11:00am ET Today - Multiple Innovative Programs in a Variety of Indications to be Discussed by BioMarin Management and External Speakers - Event Access Details Below PR N...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease PR Newswire Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, C...
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...